Objectives This study explored the association of ischemic burden, as measured by vasodilator stress cardiovascular magnetic resonance (CMR), with all-cause mortality and the effect of revascularization on all-cause mortality in patients with stable ischemic heart disease (SIHD). Background In patients with SIHD, the association of ischemic burden, derived from vasodilator stress CMR, with…
Welcome to JACC Edge, a monthly newsletter highlighting hot topics published across the family of JACC Journals. Your browser does not support the audio
Copyright © 2024, American College of Cardiology Foundation. Published by Elsevier Published online November 29,
AbstractBackgroundData on the prognostic role of the TRI-SCORE in patients undergoing transcatheter tricuspid valve intervention (TTVI) are limited.ObjectivesThe aim of this study was to evaluate…
AbstractBackgroundThe natural history of moderate/severe atrial functional mitral regurgitation (AFMR) is unknown.ObjectivesThe authors sought to study the incidence of left ventricular (LV) systol…
AbstractSodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure…
Emory University School of Medicine, Atlanta, Georgia, USA ∗Address for correspondence: Dr Oreoluwa E. Olakunle, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, Georgia…
AbstractBackgroundThe natural history of moderate/severe atrial functional mitral regurgitation (AFMR) is unknown.ObjectivesThe authors sought to study the incidence of left ventricular (LV) systol…
Welcome to JACC Edge, a monthly newsletter highlighting hot topics published across the family of JACC Journals. Your browser does not support the audio
AbstractBackgroundDepression is a known risk factor for cardiovascular disease (CVD), but the potential sex differences in this association remain unclear.ObjectivesThe aim of this study was…
JACC: CardioOncology Editor-in-chief, Bo nnie Ky, MD, MSCE, FACC and David Austin, MD, FRCP discuss PROACT, a phase three randomized open label blinded endpoint superiority…
